<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883892</url>
  </required_header>
  <id_info>
    <org_study_id>BMAC</org_study_id>
    <nct_id>NCT04883892</nct_id>
  </id_info>
  <brief_title>Evaluation of the Single Injection of BMAC vs HA in the Treatment of the Ankle Osteoarthritis</brief_title>
  <official_title>BMAC vs HA in Infiltrative Therapy for Osteoarthritis of the Ankle: Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the efficacy of the infiltrative therapy of BMAC vs HA up&#xD;
      to 24 months in the treatment of the ankle osteoarthritis. The efficacy will be assessed&#xD;
      through clinical, objective and subjective evaluations. After 12 months patients in the&#xD;
      control group can decide to cross-over in the treatment group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients who meet the inclusion criteria and giving written informed consent will be&#xD;
      randomized. We planned to enrol 120 patients.&#xD;
&#xD;
      Following the randomization, every patient will be treated with a single injection of Bone&#xD;
      Marrow Aspirate Concentrate (BMAC) or two injections of Hyaluronic Acid (HA) in the affected&#xD;
      ankle.&#xD;
&#xD;
      After the treatment patients will be followed up to 24 months whit clinical and radiological&#xD;
      assessment.&#xD;
&#xD;
      After 12 months patients in the control group can decide to cross-over in the treatment group&#xD;
      with BMAC. These patients will be followed up further 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>RCT, single-blind, allocation 1:1. After 12 months patients in the control group are allowed to cross-over in the treatment group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AOS (Ankle Osteoarthritis Scale)</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>Evaluation of the change from baseline of the OAS score, assessing the trend of pain and function up to 24 months from the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AOFAS (The American Orthopedic Foot and Ankle Score)</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>Score 0-100 made by 3 categories: Pain (0-40), Function (0-50) and Alignment (0-10).&#xD;
The best clinical and function condition is represented by a score of 100. 0 is the worst possible condition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VAS function (Visual Analog Score - function)</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>the scale is to expect the patient to select the number that best describes their functional disability status, in a range of length from 0 to 10 cm. The higher the value indicated the higher the degree of disability.</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS pain (Visual Analog Score - pain)</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>the scale is to expect the patient to select the number that best describes their pain status, in a range of length from 0 to 10 cm. The higher the value indicated the higher the degree of disability.</description>
  </other_outcome>
  <other_outcome>
    <measure>EuroQol Visual Analogue Scale (EQ-VAS)</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>0 - 100 scale where 100 is the &quot;best possible health&quot;and 0 is the &quot;worst possible health&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D (EuroQoL) Current Health Assessment</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>Score for the assessment of the quality of life of the patient.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Acceptable Symptom State (PASS)</measure>
    <time_frame>Baseline, 1, 3, 6, 12, 24 months</time_frame>
    <description>tool for assessing patient satisfaction in consideration of their current degree of pain, function and daily activity. The patient will evaluate his degree of satisfaction by answering a dichotomous closed question (yes / no).</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of the osteoarthrosis progression of the ankle joint after treatment through radiological exams</measure>
    <time_frame>12, 24 months</time_frame>
    <description>RX and MRI will be performed at 12 and 24 month after treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ankle Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>BMAC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Bone Marrow Aspirate Concentrate (BMAC) into the ankle joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two injections of Hyaluronic Acid (HA) into the ankle joint - one injection every 15 days.&#xD;
After 12 months patients are allowed to cross-over in the BMAC arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BMAC</intervention_name>
    <description>patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.&#xD;
During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability</description>
    <arm_group_label>BMAC injection</arm_group_label>
    <other_name>Bone Marrow Aspirate Concentrate injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HA</intervention_name>
    <description>patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.</description>
    <arm_group_label>HA injections</arm_group_label>
    <other_name>Hyaluronic Acid injections</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with degenerative ankle cartilage disease;&#xD;
&#xD;
          2. Unilateral involvement on the ankle;&#xD;
&#xD;
          3. Signs and symptoms of degenerative pathology of the ankle cartilage;&#xD;
&#xD;
          4. Radiographic or MRI signs of degenerative pathology of the ankle cartilage (OA Van&#xD;
             Dijk grade 1-3);&#xD;
&#xD;
          5. No clinically significant electrocardiographic changes (recently performed ECG).&#xD;
&#xD;
          6. Ability and consent of patients to actively participate in clinical follow-up;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to give consent;&#xD;
&#xD;
          2. Patients who have undergone intra-articular infiltration of another substance in the&#xD;
             preceding 6 months;&#xD;
&#xD;
          3. Patients who have undergone ankle surgery in the preceding 12 months;&#xD;
&#xD;
          4. Patients with malignant neoplasms;&#xD;
&#xD;
          5. Patients with rheumatic diseases;&#xD;
&#xD;
          6. Patients with uncompensated diabetes;&#xD;
&#xD;
        9. Patients with uncompensated thyroid metabolic disorders; 10. Patients who abuse&#xD;
        alcoholic beverages, drugs or medications; 11. Body Mass Index &gt; 35;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesca Vannini, MD</last_name>
    <phone>051-6366878</phone>
    <email>francesca.vannini@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniele Andreani, M.Sc.</last_name>
    <email>daniele.andreani@ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O'Connor MI. A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. Am J Sports Med. 2017 Jan;45(1):82-90. doi: 10.1177/0363546516662455. Epub 2016 Sep 30.</citation>
    <PMID>27566242</PMID>
  </reference>
  <reference>
    <citation>Kennedy JG, Murawski CD. The Treatment of Osteochondral Lesions of the Talus with Autologous Osteochondral Transplantation and Bone Marrow Aspirate Concentrate: Surgical Technique. Cartilage. 2011 Oct;2(4):327-36. doi: 10.1177/1947603511400726.</citation>
    <PMID>26069591</PMID>
  </reference>
  <reference>
    <citation>Giannini S, Buda R, Cavallo M, Ruffilli A, Cenacchi A, Cavallo C, Vannini F. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury. 2010 Nov;41(11):1196-203. doi: 10.1016/j.injury.2010.09.028. Epub 2010 Oct 8.</citation>
    <PMID>20934692</PMID>
  </reference>
  <reference>
    <citation>Buda R, Vannini F, Castagnini F, Cavallo M, Ruffilli A, Ramponi L, Pagliazzi G, Giannini S. Regenerative treatment in osteochondral lesions of the talus: autologous chondrocyte implantation versus one-step bone marrow derived cells transplantation. Int Orthop. 2015 May;39(5):893-900. doi: 10.1007/s00264-015-2685-y. Epub 2015 Feb 8.</citation>
    <PMID>25662594</PMID>
  </reference>
  <reference>
    <citation>Vannini F, Cavallo M, Ramponi L, Castagnini F, Massimi S, Giannini S, Buda RE. Return to Sports After Bone Marrow-Derived Cell Transplantation for Osteochondral Lesions of the Talus. Cartilage. 2017 Jan;8(1):80-87. Epub 2016 Apr 12.</citation>
    <PMID>27994723</PMID>
  </reference>
  <reference>
    <citation>Luciani D, Cadossi M, Tesei F, Chiarello E, Giannini S. Viscosupplementation for grade II osteoarthritis of the ankle: a prospective study at 18 months' follow-up. Chir Organi Mov. 2008 Dec;92(3):155-60. doi: 10.1007/s12306-008-0066-z. Epub 2008 Dec 6.</citation>
    <PMID>19067120</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone marrow aspirate concentrate</keyword>
  <keyword>hyaluronic acid</keyword>
  <keyword>BMAC</keyword>
  <keyword>HA</keyword>
  <keyword>ankle</keyword>
  <keyword>ankle injection</keyword>
  <keyword>ankle OA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

